3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Breast Neoplasms
14
Neoplasms
10
Head and Neck Neoplasms
8
Carcinoma, Squamous Cell
8
Lung Neoplasms
7
Leukemia, Myeloid, Acute
7
Glioblastoma
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Recurrence
5
Pancreatic Neoplasms
5
Melanoma
5
Leukemia
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Fallopian Tube Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Rectal Neoplasms
3
Lymphoma, Follicular
3
Colonic Neoplasms
3
Brain Neoplasms
3
Treatment
2
Sarcoma
2
Pleural Effusion, Malignant
2
Pharyngeal Neoplasms
2
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metatropic dwarfism
×
Drug Therapy
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts